Reported 1 day ago
Canaccord Genuity has initiated coverage of Mesoblast Limited (NASDAQ:MESO) with a Buy rating, setting a price target of AUD 2.97 ($1.94) per share. The firm acknowledges Mesoblast’s expertise in allogeneic therapies for severe inflammatory diseases and highlights its innovative cell therapy platform. Additionally, the company recently reported $13.2 million in gross revenue from Ryoncil sales, the first FDA-approved mesenchymal stromal cell product in the U.S., indicating strong market potential.
Source: YAHOO